Endocrine Abstracts

Background: A growing number of people in the United Kingdom are seeking medical treatment to align their sexual characteristics with their gender identity. With waiting lists for specialist clinics currently lasting over four years, endocrinologists are increasingly called upon to manage transgender care as part of their general duties. While surveys and qualitative studies from North America have investigated doctors’ ideas and experiences of transgender care, little is...

Introduction: Poorly managed transition could adversely impact upon adjustment to diabetes and potentially result in non-adherence to treatment, loss to follow-up and worsening of health-related outcomes. In our DGH, approximately 20 Young Person (YP) with T1DM get transferred to YP Clinic every year. YP between 17–19 years of age attend a joint clinic before the transfer. The YP Clinic provides a continuity of diabetes care up to the age of 25 years.<p class="abstext...

Background: Refractory hypothyroidism poses a clinical dilemma, with great difficulty to treat. Novel cases have targeted intramuscular (IM) levothyroxine (LT4) as a potential treatment for cases resistant to oral LT4. We discuss a patient who became intolerant of IM LT4 after 18 years of treatment, thus SC LT4 was initiated as alternative management.Case Presentation: 35-year-old female with diagnosed Schmidt’s Syn...

A 64-year-old female presented to the acute medical take with hypercalcaemia. She had a 3 weeks history of polyuria, polydipsia, constipation, intermittent abdominal pain and feeling depressed. She reported weight loss of 3.5 kg over the past 6 months. She denied symptoms of dysphagia, dyspnoea, haemoptysis, haematemesis, or malaena. Her past medical history included anaemia, ischaemic heart disease, chronic obstructive pulmonary disease and uterine prolapse. She was an ex-smo...

Objective: The adipocytokine visfatin, expressed in abdominal adipose tissue (AT) is thought to mimic insulin activity. However, whilst central adiposity is closely related to insulin resistance (IR) and T2DM, visfatins’ role in the development of these conditions remains unclear.Method: We investigated circulating visfatin levels in non-diabetic (ND) and diabetic (T2DM) subjects and in T2DM patients pre- and post- rosiglitazone (RSG) treatment. We ...